![Transparency Market Researchが調査・発行した産業分析レポートです。新型コロナウイルス感染症治療薬のグローバル市場（2022年-2031年）：コルチコステロイド、抗ウイルス剤、モノクローナル抗体、キナーゼ阻害剤、その他（抗炎症剤、回復期血漿、その他） / COVID-19 Therapeutics Market [Drug Class: Corticosteroids, Anti-viral, Monoclonal Antibodies, Kinase Inhibitors, and Others (Anti-inflammatory Drugs, Convalescent Plasma, Others)] - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031 / MRC2304D139資料のイメージです。](https://www.marketresearch.co.jp/images-folder2/report-contents-78.gif) | • レポートコード：MRC2304D139 • 出版社/出版日：Transparency Market Research / 2023年1月23日 • レポート形態：英文、PDF、185ページ • 納品方法：Eメール • 産業分類：医薬品 |
| Single User | ￥869,250 (USD5,795) | ▷ お問い合わせ |
| Multi User | ￥1,319,250 (USD8,795) | ▷ お問い合わせ |
| Corporate License | ￥1,769,250 (USD11,795) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Transparency Market Research社の当調査レポートでは、新型コロナウイルス感染症治療薬の世界市場を分析し、市場実態を明らかにしています。本書は、序論、仮定＆調査手法、エグゼクティブサマリー、市場概要、キーインサイト、薬剤クラス別（コルチコステロイド、抗ウイルス剤、モノクローナル抗体、キナーゼ阻害剤、その他）分析、投与経路別（経口、非経口）分析、流通チャネル別（病院薬局、小売薬局、オンライン薬局）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ）分析、競争状況などを収録しています。また、F. Hoffmann-La Roche Ltd、Gilead Sciences, Inc.、Eli Lilly and Company、Pfizer Inc.、Merck & Co., Inc.、GSK plc.、Celltrion Healthcare Co.,Ltd.、Sorrento Therapeutics, Inc.、AstraZenecaなどの企業情報を掲載しています。 ・序論 ・仮定＆調査手法 ・エグゼクティブサマリー ・市場概要 ・キーインサイト ・世界の新型コロナウイルス感染症治療薬市場規模：薬剤クラス別 - コルチコステロイドの市場規模 - 抗ウイルス剤の市場規模 - モノクローナル抗体の市場規模 - キナーゼ阻害剤の市場規模 - その他薬剤クラスの市場規模 ・世界の新型コロナウイルス感染症治療薬市場規模：投与経路別 - 新型コロナウイルス感染症経口治療薬の市場規模 - 新型コロナウイルス感染症非経口治療薬の市場規模 ・世界の新型コロナウイルス感染症治療薬市場規模：流通チャネル別 - 病院薬局チャネルの市場規模 - 小売薬局チャネルの市場規模 - オンライン薬局チャネルの市場規模 ・世界の新型コロナウイルス感染症治療薬市場規模：地域別 - 北米の新型コロナウイルス感染症治療薬市場規模 - ヨーロッパの新型コロナウイルス感染症治療薬市場規模 - アジア太平洋の新型コロナウイルス感染症治療薬市場規模 - 中南米のアルミニウムスラグ市場規模 - 中東・アフリカのアルミニウムスラグ市場規模 ・競争状況 |
COVID-19 Therapeutics Market – Scope of Report
TMR’s report on the global COVID-19 therapeutics market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2022 to 2031. The report provides revenue of the global COVID-19 therapeutics market for the period 2017–2031, considering 2022 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global COVID-19 therapeutics market from 2022 to 2031.
The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the COVID-19 therapeutics market.
Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global COVID-19 therapeutics market.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report sheds light on the changing competitive dynamics in the global COVID-19 therapeutics market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global COVID-19 therapeutics market.
The report delves into the competitive landscape of the global COVID-19 therapeutics market. Key players operating in the global COVID-19 therapeutics market have been identified and each one of these has been profiled, in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global COVID-19 therapeutics market profiled in this report.
RESEARCH METHODOLOGY
The research methodology will be a combination of exhaustive primary and secondary research to analyze the market COVID-19 therapeutics.
Secondary Research
Secondary research includes a search of company literature, technical writing, patent data, Internet sources, and statistical data from government websites, trade associations, and agencies. This has proven to be the most reliable, effective, and successful approach for obtaining precise data, capturing industry participants’ insights, and recognizing business opportunities.
Secondary research sources that we typically refer, but are not limited to:
Company websites, presentations, annual reports, white papers, technical paper, product brochure
Internal and external proprietary databases and relevant patents
National government documents, statistical databases, and market reports
News articles, press releases, and webcasts specific to companies operating in the market
Specific Secondary Sources:
• Industry Sources:
o WorldWideScience.org
o Elsevier, Inc.
o National Institutes of Health (NIH)
o PubMed
o NCBI
o Department of Health Care Service
• Trade Data Sources
o Trade Map
o UN Comtrade
o Trade Atlas
• Company Information
o OneSource Business Browser
o Hoover’s
o Factiva
o Bloomberg
• Mergers & Acquisitions
o Thomson Mergers & Acquisitions
o MergerStat
o Profound
Primary Research
During the course of research, we conduct in-depth interviews and discussions with a wide range of key industry participants and opinion leaders. Primary research represents bulk of research efforts, supplemented by extensive secondary research.
We conduct primary interviews on the ongoing basis with industry participants and commentators to validate data and analysis. A typical research interview fulfills the following functions:
Provides first-hand information on market size, market trends, growth trends, competitive landscape, outlook, etc.
Helps in validating and strengthening secondary research findings
Further develops the analysis team’s expertise and market understanding
Primary research involves e-mail interactions, telephonic interviews, as well as face-to-face interviews for each market, category, segment, and sub-segment across geographies
Participants who typically take part in such a process include, but are not limited to:
Industry participants: Marketing/product managers, market intelligence managers, and regional sales managers
Purchasing/Sourcing managers, technical personnel, distributors
Outside experts: Investment bankers, valuation experts, and research analysts specializing in specific markets
Key opinion leaders specializing in different areas corresponding to different industry verticals
List of primary participants, but not limited to:
Advanced Oncotherapy PLC
Danfysik A/S
Hitachi, Ltd.
IBA Worldwide
Mevion Medical Systems, Inc.
Data Triangulation: Information culled from “Secondary & Primary Sources” is cross-checked with “TMR Knowledge Repository”, which is updated every quarter.
Market Estimation: Market size estimations involved in-depth study of product features, technology updates, geographic presence, product demand, sales data (value or volume), historical year-on-year growth, and others. Other approaches were also utilized to derive market size and forecasts. Where no hard data was available, we employed modeling techniques in order to produce comprehensive datasets. A rigorous methodology has been adopted, wherein the available hard data are cross-referenced with the following data types to produce estimates:
Demographic Data: Healthcare expenditure, inflation rates, and others
Industry Indicators: R&D investment, technology stage, and infrastructure, sector growth, and facilities
Market Forecasting: Market forecasts for various segments are derived taking into account drivers, restraints/challenges, and opportunities prevailing in the market and considering advantages/disadvantages of segments/sub-segments over other segments/sub-segments. Business environment, historical sales pattern, unmet needs, competitive intensity, and country-wise surgery data are some of the other pivotal factors, which are considered to derive market forecasts.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary : Global COVID-19 Therapeutics Market
4. Market Overview
4.1. Introduction
4.1.1. Segment Definition
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global COVID-19 Therapeutics Market Analysis and Forecasts, 2017 – 2031
4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
5.1. Technological Advancements
5.2. Pipeline Analysis
5.3. Regulatory Scenario by Region/globally
5.4. COVID-19 Impact Analysis
6. Global COVID-19 Therapeutics Market Analysis and Forecast, by Drug Class
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Drug Class, 2017 – 2031
6.3.1. Corticosteroids
6.3.2. Anti-viral
6.3.3. Monoclonal Antibodies
6.3.4. Kinase Inhibitors
6.3.5. Others (Anti-inflammatory Drugs, Convalescent Plasma, Others)
6.4. Market Attractiveness, by Drug Class
7. Global COVID-19 Therapeutics Market Analysis and Forecast, by Route of Administration
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Route of Administration, 2017 – 2031
7.3.1. Oral
7.3.2. Parenteral
7.4. Market Attractiveness, by Route of Administration
8. Global COVID-19 Therapeutics Market Analysis and Forecast, by Distribution Channel
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, by Distribution Channel, 2017 – 2031
8.3.1. Hospital Pharmacies
8.3.2. Retail Pharmacies
8.3.3. Online Pharmacies
8.4. Market Attractiveness, by Distribution Channel
9. Global COVID-19 Therapeutics Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness, by Country/Region
10. North America COVID-19 Therapeutics Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Drug Class, 2017 – 2031
10.2.1. Corticosteroids
10.2.2. Anti-viral
10.2.3. Monoclonal Antibodies
10.2.4. Kinase Inhibitors
10.2.5. Others (Anti-inflammatory Drugs, Convalescent Plasma, Others)
10.3. Market Value Forecast, by Route of Administration, 2017 – 2031
10.3.1. Oral
10.3.2. Parenteral
10.4. Market Value Forecast, by Distribution Channel, 2017 – 2031
10.4.1. Hospital Pharmacies
10.4.2. Retail Pharmacies
10.4.3. Online Pharmacies
10.5. Market Value Forecast, by Country, 2017 – 2031
10.5.1. U.S.
10.5.2. Canada
10.6. Market Attractiveness Analysis
10.6.1. By Drug Class
10.6.2. By Route of Administration
10.6.3. By Distribution Channel
10.6.4. By Country
11. Europe COVID-19 Therapeutics Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Drug Class, 2017 – 2031
11.2.1. Corticosteroids
11.2.2. Anti-viral
11.2.3. Monoclonal Antibodies
11.2.4. Kinase Inhibitors
11.2.5. Others (Anti-inflammatory Drugs, Convalescent Plasma, Others)
11.3. Market Value Forecast, by Route of Administration, 2017 – 2031
11.3.1. Oral
11.3.2. Parenteral
11.4. Market Value Forecast, by Distribution Channel, 2017 – 2031
11.4.1. Hospital Pharmacies
11.4.2. Retail Pharmacies
11.4.3. Online Pharmacies
11.5. Market Value Forecast, by Country/Sub-region, 2017 – 2031
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Italy
11.5.5. Spain
11.5.6. Rest of Europe
11.6. Market Attractiveness Analysis
11.6.1. By Drug Class
11.6.2. By Route of Administration
11.6.3. By Distribution Channel
11.6.4. By Country/Sub-region
12. Asia Pacific COVID-19 Therapeutics Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Drug Class, 2017 – 2031
12.2.1. Corticosteroids
12.2.2. Anti-viral
12.2.3. Monoclonal Antibodies
12.2.4. Kinase Inhibitors
12.2.5. Others (Anti-inflammatory Drugs, Convalescent Plasma, Others)
12.3. Market Value Forecast, by Route of Administration, 2017 – 2031
12.3.1. Oral
12.3.2. Parenteral
12.4. Market Value Forecast, by Distribution Channel, 2017 – 2031
12.4.1. Hospital Pharmacies
12.4.2. Retail Pharmacies
12.4.3. Online Pharmacies
12.5. Market Value Forecast, by Country/Sub-region, 2017 – 2031
12.5.1. China
12.5.2. Japan
12.5.3. India
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Market Attractiveness Analysis
12.6.1. By Drug Class
12.6.2. By Route of Administration
12.6.3. By Distribution Channel
12.6.4. By Country/Sub-region
13. Latin America COVID-19 Therapeutics Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Drug Class, 2017 – 2031
13.2.1. Corticosteroids
13.2.2. Anti-viral
13.2.3. Monoclonal Antibodies
13.2.4. Kinase Inhibitors
13.2.5. Others (Anti-inflammatory Drugs, Convalescent Plasma, Others)
13.3. Market Value Forecast, by Route of Administration, 2017 – 2031
13.3.1. Oral
13.3.2. Parenteral
13.4. Market Value Forecast, by Distribution Channel, 2017 – 2031
13.4.1. Hospital Pharmacies
13.4.2. Retail Pharmacies
13.4.3. Online Pharmacies
13.5. Market Value Forecast, by Country/Sub-region, 2017 – 2031
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Market Attractiveness Analysis
13.6.1. By Drug Class
13.6.2. By Route of Administration
13.6.3. By Distribution Channel
13.6.4. By Country/Sub-region
14. Middle East & Africa COVID-19 Therapeutics Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Drug Class, 2017 – 2031
14.2.1. Corticosteroids
14.2.2. Anti-viral
14.2.3. Monoclonal Antibodies
14.2.4. Kinase Inhibitors
14.2.5. Others (Anti-inflammatory Drugs, Convalescent Plasma, Others)
14.3. Market Value Forecast, by Route of Administration, 2017 – 2031
14.3.1. Oral
14.3.2. Parenteral
14.4. Market Value Forecast, by Distribution Channel, 2017 – 2031
14.4.1. Hospital Pharmacies
14.4.2. Retail Pharmacies
14.4.3. Online Pharmacies
14.5. Market Value Forecast, by Country/Sub-region, 2017 – 2031
14.5.1. GCC Countries
14.5.2. South Africa
14.5.3. Rest of Middle East & South Africa
14.6. Market Attractiveness Analysis
14.6.1. By Drug Class
14.6.2. By Route of Administration
14.6.3. By Distribution Channel
14.6.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player – Competition Matrix (By Tier and Size of companies)
15.2. Market Share Analysis By Company (2021)
15.3. Company Profiles
15.3.1. F. Hoffmann-La Roche Ltd
15.3.1.1. Company Overview
15.3.1.2. Financial Overview
15.3.1.3. Product Portfolio
15.3.1.4. Business Strategies
15.3.1.5. Recent Developments
15.3.2. Gilead Sciences, Inc.
15.3.2.1. Company Overview
15.3.2.2. Financial Overview
15.3.2.3. Product Portfolio
15.3.2.4. Business Strategies
15.3.2.5. Recent Developments
15.3.3. Eli Lilly and Company
15.3.3.1. Company Overview
15.3.3.2. Financial Overview
15.3.3.3. Product Portfolio
15.3.3.4. Business Strategies
15.3.3.5. Recent Developments
15.3.4. Pfizer Inc.
15.3.4.1. Company Overview
15.3.4.2. Financial Overview
15.3.4.3. Product Portfolio
15.3.4.4. Business Strategies
15.3.4.5. Recent Developments
15.3.5. Merck & Co., Inc.
15.3.5.1. Company Overview
15.3.5.2. Financial Overview
15.3.5.3. Product Portfolio
15.3.5.4. Business Strategies
15.3.5.5. Recent Developments
15.3.6. GSK plc.
15.3.6.1. Company Overview
15.3.6.2. Financial Overview
15.3.6.3. Product Portfolio
15.3.6.4. Recent Developments
15.3.7. Celltrion Healthcare Co., Ltd.
15.3.7.1. Company Overview
15.3.7.2. Financial Overview
15.3.7.3. Product Portfolio
15.3.7.4. Business Strategies
15.3.7.5. Recent Developments
15.3.8. Sorrento Therapeutics, Inc.
15.3.8.1. Company Overview
15.3.8.2. Financial Overview
15.3.8.3. Product Portfolio
15.3.8.4. Business Strategies
15.3.8.5. Recent Developments
15.3.9. AstraZeneca
15.3.9.1. Company Overview
15.3.9.2. Financial Overview
15.3.9.3. Product Portfolio
15.3.9.4. Business Strategies
15.3.9.5. Recent Developments